haloperidol has been researched along with Disease Exacerbation in 21 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dynamic, 4-dimensional models of disease progression were created from 4 repeated high-resolution brain magnetic resonance imaging scans of 36 first-episode schizophrenia patients (30 men/6 women; mean age: 24." | 2.74 | Time-lapse mapping of cortical changes in schizophrenia with different treatments. ( Bartzokis, G; Charles, C; Edwards, N; Geaga, JA; Hamer, RM; Hayashi, KM; Hong, MS; Klunder, AD; Lieberman, JA; Lu, PH; McEvoy, J; Perkins, DO; Thompson, PM; Toga, AW; Tohen, M; Tollefson, GD; Yu, M, 2009) |
| "As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms." | 2.71 | Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. ( Delbello, MP; Glick, I; Green, AI; Hamer, RM; Johnson, JL; Lieberman, JA; Patel, JK; Strakowski, SM; Tohen, M, 2005) |
| "Haloperidol dose was negatively associated with improvement in positive symptoms (r = -." | 2.68 | Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. ( Pardo, M; Pollack, S; Weisbard, JJ, 1997) |
| "The increasing recognition of Tourette's syndrome is probably responsible for the broadening range of symptom severities seen in clinic patients." | 2.39 | Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. ( Peterson, BS, 1996) |
| "This case reminds us that Sydenham's chorea can result in major functional impairment." | 1.43 | Successful treatment of Sydenham's chorea with intravenous immunoglobulin. ( Boersma, NA; Heidema, J; Kuijpers, T; Schippers, H, 2016) |
| "The cause of Parkinsonism has been described as wide and elusive, however, environmental toxins and drugs accounts for large percentage of spontaneous cases in humans." | 1.42 | -NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism. ( Abdulbasit, A; Balogun, WG; Cobham, AE; Enye, LA; Ishola, AO; Nanakumo, ET; Obende, OM; Ogundele, OM, 2015) |
| "UHDRS (Unified Huntington's Disease Rating Scale) motor scores were obtained from medical records as an index of disease progression." | 1.42 | Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. ( Cimino, CR; Hergert, DC; Sanchez-Ramos, J, 2015) |
| " We found substantial differences in baseline characteristics of subjects, administered dosage and disease severity in India compared to the USA and Russia." | 1.37 | Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. ( Lombardo, I; Mandel, FS; Pappadopulos, E; Vieta, E, 2011) |
| "Acquired hepatocerebral degeneration (AHD) and hepatolenticular degeneration can have similar clinical presentations, but when a chronic liver disease and atypical motor findings coexist, the distinction between AHD and hepatic encephalopathy (HE) can be even more complicated." | 1.37 | Acquired hepatocerebral degeneration and hepatic encephalopathy: correlations and variety of clinical presentations in overt and subclinical liver disease. ( Américo, MF; Caramori, CA; Romeiro, FG; Santos, AC; Schelp, AO; Silva, GF; Yamashiro, FS, 2011) |
| "Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases." | 1.34 | Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. ( Jarskog, LF; Lieberman, JA; Perkins, DO, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Regan, DW | 1 |
| Kashiwagi, D | 1 |
| Dougan, B | 1 |
| Sundsted, K | 1 |
| Mauck, K | 1 |
| El-Sayeh, HG | 1 |
| Rathbone, J | 1 |
| Soares-Weiser, K | 1 |
| Bergman, H | 1 |
| Ogundele, OM | 1 |
| Nanakumo, ET | 1 |
| Ishola, AO | 1 |
| Obende, OM | 1 |
| Enye, LA | 1 |
| Balogun, WG | 1 |
| Cobham, AE | 1 |
| Abdulbasit, A | 1 |
| Hergert, DC | 1 |
| Sanchez-Ramos, J | 1 |
| Cimino, CR | 1 |
| Boersma, NA | 1 |
| Schippers, H | 1 |
| Kuijpers, T | 1 |
| Heidema, J | 1 |
| Kelley, ME | 1 |
| Haas, GL | 1 |
| van Kammen, DP | 1 |
| Thompson, PM | 1 |
| Bartzokis, G | 1 |
| Hayashi, KM | 1 |
| Klunder, AD | 1 |
| Lu, PH | 1 |
| Edwards, N | 1 |
| Hong, MS | 1 |
| Yu, M | 1 |
| Geaga, JA | 1 |
| Toga, AW | 1 |
| Charles, C | 1 |
| Perkins, DO | 2 |
| McEvoy, J | 1 |
| Hamer, RM | 2 |
| Tohen, M | 2 |
| Tollefson, GD | 1 |
| Lieberman, JA | 3 |
| Bastiampillai, T | 1 |
| Dhillon, R | 1 |
| Mohindra, R | 1 |
| Danilov, DS | 1 |
| Cerimele, JM | 1 |
| Stern, AP | 1 |
| Jutras-Aswad, D | 1 |
| Vieta, E | 1 |
| Pappadopulos, E | 1 |
| Mandel, FS | 1 |
| Lombardo, I | 1 |
| Romeiro, FG | 1 |
| Américo, MF | 1 |
| Yamashiro, FS | 1 |
| Caramori, CA | 1 |
| Schelp, AO | 1 |
| Santos, AC | 1 |
| Silva, GF | 1 |
| Bachus, SE | 1 |
| Yang, E | 1 |
| McCloskey, SS | 1 |
| Minton, JN | 1 |
| Schennach, R | 1 |
| Riesbeck, M | 1 |
| Mayr, A | 1 |
| Seemüller, F | 1 |
| Maier, W | 1 |
| Klingberg, S | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Gastpar, M | 1 |
| Schmitt, A | 1 |
| Sauer, H | 1 |
| Schneider, F | 1 |
| Jäger, M | 1 |
| Wölwer, W | 1 |
| Gaebel, W | 1 |
| Möller, HJ | 1 |
| Riedel, M | 1 |
| Goto, Y | 1 |
| O'Donnell, P | 1 |
| Strakowski, SM | 1 |
| Johnson, JL | 1 |
| Delbello, MP | 1 |
| Green, AI | 1 |
| Glick, I | 1 |
| Patel, JK | 1 |
| Jarskog, LF | 1 |
| Peterson, BS | 1 |
| Weisbard, JJ | 1 |
| Pardo, M | 1 |
| Pollack, S | 1 |
| Bonelli, RM | 1 |
| Költringer, P | 1 |
| Kenner, L | 1 |
| Reisecker, F | 1 |
| Bonelli, R | 1 |
| Coffey, BJ | 1 |
| Biederman, J | 1 |
| Geller, DA | 1 |
| Spencer, T | 1 |
| Park, KS | 1 |
| Shapiro, SJ | 1 |
| Garfield, SB | 1 |
4 reviews available for haloperidol and Disease Exacerbation
| Article | Year |
|---|---|
Update in perioperative medicine: practice changing evidence published in 2016.
Topics: Amines; Analgesics; Anticoagulants; Antipsychotic Agents; Arthritis, Rheumatoid; Blood Transfusion; | 2017 |
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Anti-Dyskinesia Agents; Antipsychotic Agents; Celiprolol; Disease Prog | 2018 |
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseas | 1996 |
The course of Tourette's disorder: a literature review.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Comorbidity; Disease Progression; Europe; Haloperido | 2000 |
4 trials available for haloperidol and Disease Exacerbation
| Article | Year |
|---|---|
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Disease Progression; Female; Hal | 2009 |
Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
Topics: Adult; Antipsychotic Agents; Disease Progression; Double-Blind Method; Female; Haloperidol; Humans; | 2013 |
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Disease Progression; Double-Blind Method; Female; Foll | 2005 |
Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Disease Prog | 1997 |
13 other studies available for haloperidol and Disease Exacerbation
| Article | Year |
|---|---|
-NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Calcium; Cognition Disorders; Disease Models, Animal; Disease | 2015 |
Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Topics: Adult; Aged; Antipsychotic Agents; Awareness; Cognition Disorders; Disease Progression; Female; Fron | 2015 |
Successful treatment of Sydenham's chorea with intravenous immunoglobulin.
Topics: Anti-Bacterial Agents; Child; Chorea; Disease Progression; Female; Haloperidol; Humans; Immunoglobul | 2016 |
Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.
Topics: Adult; Age of Onset; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Cohort Studies; Dis | 2008 |
Exacerbation of tics secondary to clozapine therapy.
Topics: Agranulocytosis; Antipsychotic Agents; Clozapine; Disease Progression; Dose-Response Relationship, D | 2008 |
[The possibility of high-quality remission in the long chronic course of schizophrenia].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Disease Progression; Drug Therapy, Co | 2008 |
Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Arousal; Beverages; Caffeine; Central Nervous System Stimulants | 2010 |
Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Cultural Characteristics; Disease Progres | 2011 |
Acquired hepatocerebral degeneration and hepatic encephalopathy: correlations and variety of clinical presentations in overt and subclinical liver disease.
Topics: Anti-Dyskinesia Agents; Diagnosis, Differential; Disease Progression; Female; Haloperidol; Hepatic E | 2011 |
Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Autoradiography; Behavior, A | 2012 |
Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.
Topics: Administration, Oral; Age Factors; Animals; Animals, Newborn; Corpus Striatum; Disease Models, Anima | 2002 |
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition | 2007 |
Reversible Huntington's disease?
Topics: Antipsychotic Agents; Caudate Nucleus; Disease Progression; Haloperidol; Humans; Huntington Disease; | 1998 |